Efficacy and Safety of T+A+RAD in HCC

NCT05396937 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

RADIATION: Multifocal Stereotactic Radiotherapy
DRUG: Atezolizumab Injection [Tecentriq]
DRUG: Bevacizumab

Sponsor

Fudan University

Collaborators

[object Object]